Veru Inc. is an oncology and urology biopharmaceutical company developing novel medicines for the prostate cancer continuum of care and urology specialty pharmaceuticals.

Pipeline of proprietary product candidates and specialty pharmaceuticals

The Veru prostate cancer pipeline includes VERU-111 (bisindole), zuclomiphene citrate (also known as VERU-944, cis-clomiphene) and VERU-100. VERU-111 is an oral, next-generation, first-in-class selective small molecule that targets and disrupts alpha and beta tubulin subunits of microtubules in cells to treat metastatic prostate cancer patients whose disease is resistant to both castration and novel androgen blocking agents (abiraterone or enzalutamide). VERU-111 is being evaluated in men with metastatic castration and androgen-blocking agent resistant prostate cancer in an open label Phase 1b/2 clinical trial. Zuclomiphene citrate is an oral estrogen receptor agonist being evaluated in a Phase 2 trial to treat hot flashes, a common side effect caused by hormone treatment for men with advanced prostate cancer. VERU-100 is a novel, proprietary peptide formulation designed with multiple beneficial clinical attributes addressing the shortfalls of the current multi-billion-dollar androgen deprivation therapy market for advanced prostate cancer. VERU-100 is a long-acting gonadotropin-releasing hormone (GnRH) antagonist designed to be administered as a small volume subcutaneous 3-month depot injection without a loading dose. VERU-100 will immediately suppress testosterone with no testosterone surge upon initial or repeated administration — a problem which occurs with currently approved LHRH agonists. Currently, there are no GnRH antagonists commercially approved beyond 1 month. VERU-100 is anticipated to enter Phase 2 dose finding study in early 2020.

Veru is also advancing new drug formulations in its specialty pharmaceutical pipeline addressing unmet medical needs in urology such as the Tadalafil and Finasteride Combination (TADFIN®) formulation for the administration of tadalafil 5mg and finasteride 5mg combination formulation dosed daily for benign prostatic hyperplasia (BPH). Tadalafil (CIALIS®) is currently approved for treatment of BPH and erectile dysfunction and finasteride is currently approved for treatment BPH (finasteride 5mg PROSCAR®) and male pattern hair loss (finasteride 1mg PROPECIA®). The co-administration of tadalafil and finasteride has been shown to be more effective for the treatment of BPH than by finasteride alone.* Expected submission of the NDA for TADFIN® is summer of 2020. Veru is also developing Tamsulosin DRS granules and Tamsulosin XR capsules which are formulations of tamsulosin, the active ingredient in FLOMAX®, which Veru has designed to avoid the “food effect” inherent in currently marketed formulations of the drug, allowing for potentially safer administration and improved patient compliance.

*Casabe A et al. J or Urol 2014; 191:717-733

CURRENT PIPELINE

VERU-111

VERU-111

A novel oral selective antitubulin that targets alpha and beta tubulin for metastatic prostate cancer as well as for other forms of advanced cancers.

Zuclomiphene citrate

Zuclomiphene citrate

Estrogen receptor agonist for the treatment of hot flashes caused by prostate cancer hormonal therapies in men with advanced prostate cancer.

VERU-100

VERU-100

VERU-100 is a novel, proprietary peptide formulation designed with multiple beneficial clinical attributes addressing the shortfalls of the current multi-billion-dollar androgen deprivation therapy market for advanced prostate cancer.

Tadalafil 5mg and Finasteride 5mg combination capsule (TADFIN®)

Tadalafil 5mg and Finasteride 5mg combination capsule (TADFIN®)

TADFIN® combination of a PDE5 inhibitor and 5 alpha reductase inhibitor for the treatment of enlarged prostate (BPH)

VERU IS ENROLLING PATIENTS

VERU-111

CLINICAL TRIALS

To Evaluate the Safety and Tolerability of VERU-111 in Men with Advanced Metastatic Castration Resistant Prostate Cancer

Zuclomiphene Citrate

CLINICAL TRIALS

To Ameliorate the Vasomotor Symptoms (Hot Flashes) Resulting from Androgen Deprivation Therapy in Men with Advanced Prostate Cancer